The Impact of Family History and Genetic Risk Score on Prostate Cancer Screening in 700 Patients Twelve Years After Randomization
Document Type
Conference Proceeding - Restricted Access
Publication Date
5-9-2025
Abstract
The use of genetic risk scores (GRS) is an effective tool for identifying patients who develop prostate cancer (PCa), especially in younger patients when used in conjunction with family history. Patients with GRS >1.5 (18%) have a two-fold risk of PCa incidence and mortality. Effective risk stratification of patients based on GRS may help tailor the use of prostate-specific antigen (PSA) screening to facilitate detection of PCa. This study builds on existing research by analyzing the impact of GRS on PSA screening to reduce over-diagnosis and unnecessary treatments. We evaluated whether family history (FH) and GRS impacted PSA screening and evaluation in 700 patients during the 12 years following enrollment in a randomized clinical trial (RCT) of GRS. Our findings may inform clinicians on the utility of using genetic tools with PSA screening to improve PCa risk assessment and outcomes.
Recommended Citation
Garcia V, Shafau F, Noyes S, Taylor C, Lane BR. The impact of family history and genetic risk score on prostate cancer screening in 700 patients twelve years after randomization. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.
Comments
2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1828